Gulf War Illness Clinical Trial
Official title:
Cognitive Rehabilitation for Gulf War Illness
Verified date | August 2020 |
Source | VA Office of Research and Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
There are almost 700,000 Gulf War Veterans (GWV) with 25-30% suffering from a devastating multi-symptom illness coined Gulf War Illness (GWI). GWV with GWI report significant activity limitations and chronic cognitive problems consistent with problem-solving deficits. Problem-solving is considered the most complex of cognitive abilities and is what enables us to conduct complicated behaviors such as setting goals, sequencing and multi-tasking. As a result studies have found that problem-solving deficits are prospectively related to a greater risk of disability. Despite published reports documenting these problems there are no treatments that target the problem-solving deficits of GWI. This proposal seeks to determine whether Problem-Solving Therapy, a patient centered cognitive rehabilitation therapy, can reduce disability by compensating for problem-solving deficits.
Status | Completed |
Enrollment | 268 |
Est. completion date | September 1, 2019 |
Est. primary completion date | December 31, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: Inclusion: - deployed to first Gulf War and meets Kansas definition for GWI (see definition in measures section); - scores at least a half a standard deviation worse than the mean on the World Health Organization Disability Schedule (WHO-DAS II). Exclusion Criteria: Exclusion: - current suicidal/homicide intent or plan assessed by The Columbia Suicide Severity Rating Scale, schizophrenia or current psychotic symptoms - self-reported diagnosis of a degenerative brain disorder or serious psychiatric or medical illness which may limit generalizability of the findings, limit safety or account for the symptoms of GWI. Exclusionary medical illnesses include: Class 3 and 4 heart failure, cancer diagnosed within the past year and/or undergoing active treatment (chemotherapy or radiation therapy), chronic renal insufficiency, hospitalization due to myocardial infarct, stroke in the past year, a neurodegenerative disorder, or another medical or psychiatric disorder that may limit generalizability, limit participants safety or account for the symptoms of GWI at the discretion of the PI. - a disability that would preclude telephone use. |
Country | Name | City | State |
---|---|---|---|
United States | Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA | Bedford | Massachusetts |
United States | Canandaigua VA Medical Center, Canandaigua, NY | Canandaigua | New York |
United States | East Orange Campus of the VA New Jersey Health Care System, East Orange, NJ | East Orange | New Jersey |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Pain Disability Change | Pain Disability Index (PDI). Scale ranges from 0-70 with higher scores meaning worse disability. | Baseline and 12 weeks | |
Other | Multidimensional Pain Inventory - Pain Severity Subscale Change | three items assessing pain severity. scores range 0-18 with higher scores=worse severity | baseline and 12 weeks | |
Other | Fatigue Change | The Fatigue Severity Scale (FSS). Scale from 9 to 63 with higher scores = worse fatigue | Baseline and 12 weeks | |
Primary | Disability - WHO-DAS 2 Change | World Health Organization Disability Assessment Schedule. The WHO-DAS 2.0 measures disability due to physical and mental health conditions. The WHO-DAS 2.0 is a 36 item measure that focuses upon six life tasks: Understanding and communicating Self-care Mobility (getting around) Interpersonal relationships (getting along with others) Work and household roles (life activities) Community and civic roles (participation) These six life tasks reflect two underlying constructs: Activity limitations and Participation deficits. Scores range from 0-100 with higher scores = more disability. |
Baseline and 12 weeks | |
Secondary | Problem-Solving Inventory Change | Self-report problem-solving ability. Scores range from 32-192 with lower scores equally better problem-solving ability. | Baseline and 12 weeks | |
Secondary | Problem-Solving Ability Change | Neuropsychological Battery includes: Halstead Category Test, Russell Revised Version, The Conner's Continuous Performance Test-3 (CPT-3), Stroop Color and Word Test, Trails Making Test A and B (TMT). Problem-solving ability was be created by standardizing (i.e., converting to z-scores) these neuropsychological tests based on administrative norms and averaging them. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched). Negative numbers indicate values lower than the reference population and positive numbers indicate values higher than the reference population and higher scores reflecting greater problem solving. | Baseline and 12 weeks | |
Secondary | Disability - WHO-DAS 2 Change | World Health Organization Disability Assessment Schedule. The WHO-DAS 2.0 measures disability due to physical and mental health conditions. The WHO-DAS 2.0 is a 36 item measure that focuses upon six life tasks: Understanding and communicating Self-care Mobility (getting around) Interpersonal relationships (getting along with others) Work and household roles (life activities) Community and civic roles (participation) These six life tasks reflect two underlying constructs: Activity limitations and Participation deficits. Scores range from 0-100 with higher scores = more disability. |
Baseline and 6 months | |
Secondary | Problem-Solving Inventory Change | Self-report problem-solving ability. Scores range from 32-192 with lower scores equally better problem-solving ability. | Baseline and 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04254627 -
TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset
|
Phase 1 | |
Terminated |
NCT02011542 -
Probiotic (VSL #3) for Gulf War Illness
|
Phase 2/Phase 3 | |
Recruiting |
NCT03078530 -
Probiotic (Visbiome) for Gulf War Illness
|
Phase 2/Phase 3 | |
Recruiting |
NCT04058275 -
"Immunomodulation in GWI (Phlebotomy)"
|
||
Recruiting |
NCT04255498 -
Understanding GWI: Integrative Modeling
|
Phase 1 | |
Completed |
NCT02782780 -
Cognitive Behavioral Therapy for Insomnia for Gulf War Illness
|
N/A | |
Recruiting |
NCT02983734 -
D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS)
|
Phase 2 | |
Recruiting |
NCT05972291 -
Mechanisms of Gulf War Illness
|
N/A | |
Recruiting |
NCT04046536 -
rTMS in Alleviating Pain and Co-Morbid Symptoms in Gulf War Veterans Illness (GWVI)
|
N/A | |
Recruiting |
NCT04182659 -
Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms
|
N/A | |
Recruiting |
NCT05377242 -
Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI
|
N/A | |
Recruiting |
NCT05675878 -
Confirmation of Diet as a Treatment for Gulf War Illness
|
Phase 3 | |
Recruiting |
NCT05736146 -
Validating Gulf War Illness Blood Biomarkers
|
||
Not yet recruiting |
NCT05820893 -
Resistant Potato Starch to Alleviate GWI
|
Phase 2 | |
Terminated |
NCT01846182 -
Research Examining Gulf War Illness in Our Nations Service Members
|
Phase 2 | |
Active, not recruiting |
NCT05252949 -
OEA for Targeting Lipid Metabolism in GWI
|
N/A | |
Completed |
NCT02378025 -
Treating Chronic Pain in Gulf War Illness
|
N/A | |
Completed |
NCT02865460 -
Coenzyme Q10 Phase III Trial in Gulf War Illness
|
Phase 3 | |
Completed |
NCT02909686 -
Effects of Botanical Microglia Modulators in Gulf War Illness
|
N/A | |
Completed |
NCT01291758 -
Exercise in Gulf War Illness (GWI)
|